Trial Profile
A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002158 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects with Chronic Hepatitis C Genotype 1 Infection.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ALS 2158 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Alios BioPharma
- 26 Sep 2012 Secondary endpoint 'Viral-kinetic-parameters' has not been met.
- 30 Jul 2012 Results are expected by the end of 2012 according to a Vertex Pharmaceuticals media release.
- 13 Mar 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.